J Pathol Transl Med.  2021 May;55(3):181-191. 10.4132/jptm.2021.03.23.

Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

• Chang S
• Shim HS
• Kim TJ
• Choi YL
• Kim WS
• Shin DH
• Kim L
• Park HS
• Lee GK
• Lee CH
• Korean Cardiopulmonary Pathology Study Group

• KMID: 2515923
• DOI: http://doi.org/10.4132/jptm.2021.03.23

Abstract

Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group co-published a molecular testing guideline which contained almost all known genetic changes that aid in treatment decisions or predict prognosis in patients with NSCLC. Since then there have been significant changes in targeted therapies as well as molecular testing including newly approved targeted drugs and liquid biopsy. In order to reflect these changes, the Korean Cardiopulmonary Pathology Study Group developed a consensus statement on molecular biomarker testing. This consensus statement was crafted to provide guidance on what genes should be tested, as well as methodology, samples, patient selection, reporting and quality control.

Keyword

Carcinoma, non-small-cell lung; Biomarker; Precision medicine; Consensus

Reference

References

1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29:2866–74.

2. Shim HS, Chung JH, Kim L, et al. Guideline recommendations for EGFR mutation testing in lung cancer: proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol. 2013; 47:100–6.

3. Kim H, Shim HS, Kim L, et al. Guideline recommendations for testing of ALK gene rearrangement in lung cancer: a proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol. 2014; 48:1–9.

4. Shim HS, Choi YL, Kim L, et al. Molecular testing of lung cancers. J Pathol Transl Med. 2017; 51:242–54.

5. Shin DH, Shim HS, Kim TJ, et al. Provisional guideline recommendation for EGFR gene mutation testing in liquid samples of lung cancer patients: a proposal by the Korean Cardiopulmonary Pathology Study Group. J Pathol Transl Med. 2019; 53:153–8.

6. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018; 142:321–46.

7. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018; 36:911–9.

8. Ettinger DS, Wood DE, Aisner DL, et al. NCCN Clinical practice guidelines in oncology (NCCN Guidelines) for non-small cell lung cancer, version 8.2020 [Internet]. Plymouth Meeting: National Comprehensive Cancer Network;2020 [cited 2020 Oct 15]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

9. Genova C, Rossi G, Tagliamento M, et al. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. Expert Rev Respir Med. 2020; 14:367–83.

10. Del Re M, Cucchiara F, Petrini I, et al. erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open. 2020; 5:e000724.

11. Yoon HY, Ryu JS, Sim YS, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study. PLoS One. 2020; 15:e0228925.

12. Choi CM, Kim HC, Jung CY, et al. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Res Treat. 2019; 51:1400–10.

13. Lee SH, Kim WS, Choi YD, et al. Analysis of mutations in epidermal growth factor receptor gene in Korean patients with non-small cell lung cancer: summary of a nationwide survey. J Pathol Transl Med. 2015; 49:481–8.

14. Janne PA. Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer. 2008; 60 Suppl 2:S3–9.

15. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693–703.

16. Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol. 2018; 2018:PO.18.00037.

17. Ghimessy A, Radeczky P, Laszlo V, et al. Current therapy of KRASmutant lung cancer. Cancer Metastasis Rev. 2020; 39:1159–77.

18. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019; 39:531–42.

19. Rolfo C, Cardona AF, Cristofanilli M, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020; 151:102978.

20. Tafe LJ. Non-small cell lung cancer as a precision oncology paradigm: emerging targets and tumor mutational burden (tmb). adv anat pathol. 2020; 27:3–10.

21. marabelle a, fakih m, lopez j, et al. association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 keynote-158 study. lancet oncol. 2020; 21:1353–65.

22. uruga h, mino-kenudson m. alk (d5f3) cdx: an immunohistochemistry assay to identify alk-positive nsclc patients. pharmgenomics pers med. 2018; 11:147–55.

23. marchio c, scaltriti m, ladanyi m, et al. esmo recommendations on the standard methods to detect ntrk fusions in daily practice and clinical research. ann oncol. 2019; 30:1417–27.

24. ku bm, heo mh, kim jh, et al. molecular screening of small biopsy samples using next-generation sequencing in korean patients with advanced non-small cell lung cancer: korean lung cancer consortium (klcc-13-01). j pathol transl med. 2018; 52:148–56.

25. bruno r, fontanini g. next generation sequencing for gene fusion analysis in lung cancer: a literature review. diagnostics (basel). 2020; 10:521.

26. kim j, park wy, kim nk, et al. good laboratory standards for clinical next-generation sequencing cancer panel tests. j pathol transl med. 2017; 51:191–204.

27. lee se, lee sy, park hk, et al. detection of egfr and kras mutation by pyrosequencing analysis in cytologic samples of non-small cell lung cancer. j korean med sci. 2016; 31:1224–30.

28. sun pl, jin y, kim h, lee ct, jheon s, chung jh. high concordance of egfr mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. cancer cytopathol. 2013; 121:311–9.

29. asaka s, yoshizawa a, nakata r, et al. utility of bronchial lavage fluids for epithelial growth factor receptor mutation assay in lung cancer patients: comparison between cell pellets, cell blocks and matching tissue specimens. oncol lett. 2018; 15:1469–74.

30. roy-chowdhuri s, chen h, singh rr, et al. concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. mod pathol. 2017; 30:499–508.

31. shiau cj, babwah jp, da cunha santos g, et al. sample features associated with success rates in population-based EGFR mutation testing. j thorac oncol. 2014; 9:947–56.

32. da cunha santos g, wyeth t, reid a, et al. a proposal for cellularity assessment for egfr mutational analysis with a correlation with dna yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. j clin pathol. 2016; 69:607–11.

33. roy-chowdhuri s, aisner dl, allen tc, et al. biomarker testing in lung carcinoma cytology specimens: a perspective from members of the pulmonary pathology society. arch pathol lab med. 2016; 140:1267–72.

34. lozano md, echeveste ji, abengozar m, et al. cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less. arch pathol lab med. 2018; 142:291–8.

35. jain d, roy-chowdhuri s. molecular pathology of lung cancer cytology specimens: a concise review. arch pathol lab med. 2018; 142:1127–33.

36. da cunha santos g, saieg ma, troncone g, zeppa p. cytological preparations for molecular analysis: a review of technical procedures, advantages and limitations for referring samples for testing. cytopathology. 2018; 29:125–32.

37. auger m, brimo f, kanber y, fiset po, camilleri-broet s. a practical guide for ancillary studies in pulmonary cytologic specimens. cancer cytopathol. 2018; 126 suppl 8:599–614.

38. aisner dl. the revised college of american pathologists/international association for the study of lung cancer/association for molecular pathology guideline: a step forward for molecular cytopathology. arch pathol lab med. 2018; 142:684–5.

39. chang s, hur jy, choi yl, lee ch, kim ws. current status and future perspectives of liquid biopsy in non-small cell lung cancer. j pathol transl med. 2020; 54:204–12.

40. nosaki k, satouchi m, kurata t, et al. re-biopsy status among nonsmall cell lung cancer patients in japan: a retrospective study. lung cancer. 2016; 101:1–8.

41. siravegna g, marsoni s, siena s, bardelli a. integrating liquid biopsies into the management of cancer. nat rev clin oncol. 2017; 14:531–48.

42. passiglia f, rizzo s, di maio m, et al. the diagnostic accuracy of circulating tumor dna for the detection of egfr-t790m mutation in nsclc: a systematic review and meta-analysis. sci rep. 2018; 8:13379.

43. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016; 34:3375–82.

44. remon j, caramella c, jovelet c, et al. osimertinib benefit in EGFR-mutant nsclc patients with t790m-mutation detected by circulating tumour dna. ann oncol. 2017; 28:784–90.

45. aisner dl, rumery md, merrick dt, et al. do more with less: tips and techniques for maximizing small biopsy and cytology specimens for molecular and ancillary testing: the university of colorado experience. arch pathol lab med. 2016; 140:1206–20.

46. Cobas EGFR mutation test v2 [Internet]. Silver Spring: U.S. Food and Drug Administration;2020 [cited 2020 oct 15]. available from: https://www.accessdata.fda.gov/cdrh_docs/pdf12/p120019s007c.pdf.

47. lim c, sekhon hs, cutz jc, et al. improving molecular testing and personalized medicine in non-small-cell lung cancer in ontario. curr oncol. 2017; 24:103–10.

48. anand k, phung tl, bernicker eh, cagle pt, olsen rj, thomas js. clinical utility of reflex ordered testing for molecular biomarkers in lung adenocarcinoma. clin lung cancer. 2020; 21:437–42.

49. cheema pk, menjak ib, winterton-perks z, et al. impact of reflex egfr/ alk testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. j oncol pract. 2017; 13:e130–8.

50. indini a, rijavec e, bareggi c, grossi f. novel treatment strategies for early-stage lung cancer: the oncologist's perspective. j thorac dis. 2020; 12:3390–8.

51. wu yl, tsuboi m, he j, et al. osimertinib in resected egfr-mutated non-small-cell lung cancer. n engl j med. 2020; 383:1711–23.

52. pelosi g, fabbri a, bianchi f, et al. deltanp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparingmaterial approach. j thorac oncol. 2012; 7:281–90.

53. Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med. 2014; 138:1520–30.

54. Compton CC, Robb JA, Anderson MW, et al. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med. 2019; 143:1346–63.

55. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjo A. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol. 2013; 121:344–53.

56. Miquelestorena-Standley E, Jourdan ML, Collin C, et al. Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples. Mod Pathol. 2020; 33:1505–17.

57. Choi SE, Hong SW, Yoon SO. Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study. J Pathol Transl Med. 2015; 49:236–42.

58. COSMIC (catalogue of somatic mutations in cancer) [Internet]. COSMIC;2020 [cited 2020 Oct 15]. Available from: https://cancer.sanger.ac.uk/cosmic.

59. Wang H, Sun L, Sang Y, et al. A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. Lung Cancer. 2019; 130:135–42.

60. Paik PK, Varghese AM, Sima CS, et al. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Mol Cancer Ther. 2012; 11:2535–40.

61. Dragnev KH, Gehr G, Memoli VA, Tafe LJ. ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies. Clin Lung Cancer. 2014; 15:e37–40.

62. Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. BMC Cancer. 2017; 17:471.

63. Lin G, Li C, Li PS, et al. Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. Ann Oncol. 2020; 31:517–24.

64. Sholl LM, Hirsch FR, Hwang D, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020; 15:1409–24.

65. Sakai K, Takahama T, Shimokawa M, et al. Predicting osimertinibtreatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Mol Oncol. 2021; 15:126–37.